Simply hold the mid-infrared laser to your hand to measure blood sugar levels in just 5 seconds. This startup offers safe and convenient blood glucose monitoring that eliminates the need for blood sampling, reducing physical and mental burden while minimizing infection risks and medical waste.
[画像1: https://prtimes.jp/i/82314/9/resize/d82314-9-cd857c03a3cf744b5f3e-0.jpg ] 世界初の指で触れるだけで、採血なしに血糖値が測定できる非侵襲血糖値センサーの開発を行うライトタッチテクノロジー株式...
[画像1: https://prtimes.jp/i/82314/3/resize/d82314-3-e06dbe49872c4e5ed04e-0.jpg ] LTT社は糖尿病患者の方々の採血による血糖値測定に際する苦痛・ストレスの緩和、感染症リスクの低減、並びに糖尿病予備...
[画像1: https://prtimes.jp/i/82314/2/resize/d82314-2-1be3ad78c18aff849495-0.png ]   世界初の採血のいらない非侵襲血糖値センサーの開発を行うライトタッチテクノロジー（Light Touch Technology:...
At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.
As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.
Development of small-molecule therapeutics targeting RNA.
Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.